+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID07372287

Phase 3 Study of CM326 Injection for Treating Moderate to Severe Asthma in Adults

Led by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Updated on 2026-04-28

230

Participants Needed

1

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of CM326 in adults with moderate to severe asthma. This Phase III, multi-center, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, pharmacokinetics, pharmacodynamics, and immune response to CM326 in this population. The study is sponsored by CSPC Baike Shandong Biopharmaceutical Co., Ltd. and focuses on reducing severe asthma exacerbations and improving lung function. The study involves three periods up to 4 weeks of screening to confirm eligibility, followed by a 52-week double-blind randomized treatment period where participants receive either CM326 or a placebo by subcutaneous injection, and finally a 12-week safety follow-up period. Participants receive either CM326 or placebo injections, with treatment and follow-up visits scheduled throughout these periods to monitor effects and safety. Participants will undergo regular lung function tests including measurements like forced expiratory volume FEV1, asthma control questionnaires, and quality of life assessments. Researchers will monitor for severe asthma attacks, need for emergency care, medication use, and collect blood samples to evaluate drug levels, immune responses, and inflammation markers. The study also tracks adverse events and overall health during and after treatment, with total participation lasting around 68 weeks.

CONDITIONS

Brief Title

A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

Research Team

C

Clinical Trials Information Group officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here